Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece

Real-world studies have demonstrated the effectiveness of automated insulin delivery systems in managing people with type 1 diabetes (T1D) worldwide. However, data on the effectiveness of such systems in the management of people with T1D in Greece have previously been lacking. This retrospective analysis sought to address this by providing real-world insights into the impact of the MiniMed 780G system on the glycemic control of people with T1D in Greece.

Data from MiniMed 780G systems, uploaded to the CareLink Personal Software program between January 2024 and January 2025 by 2284 users with T1D in Greece, were collected and analyzed. Outcomes considered included glycemic control measures such as time spent in target ranges, glucose management indicator (GMI), and international glycemic control targets. Data were analyzed across different age groups (≤ 15 years, 16-55 years, ≥ 56 years), with additional analyses of cohorts using recommended optimal settings (ROS), users with data from before and after the initiation of the advanced hybrid closed-loop system, and users with 12 months of data.

Across the overall cohort, the mean (standard deviation [SD]) time in range (TIR) was 75.4% (9.5%), and 59.3% of users achieved a combined target of a GMI < 7%, TIR > 70%, time below 70 mg/dl < 4%, and time below 54 mg/dl < 1%. These findings were consistent across age groups and stable over a 12-month period, but were found to be better among users with ROS. Comparing data obtained before and after the initiation of the system, mean (SD) TIR was found to increase from 65.1% (13.9%) to 74.9% (9.6%), while the proportion of users achieving a TIR of > 70% increased from 36.1 to 72.8%.

These data demonstrate that most users of the MiniMed 780G system achieve the recommended glycemic control targets.